PATIENTS ARRIVED AT
SIGNIFICANT REDUCTIONS

Comedonal (noninflammatory) lesion reductions
at 12 weeks1,2*

Female patients comedonal reductions charttFemale patients comedonal reductions chartFemale patients comedonal reductions chart

Results of a phase 3, multicenter, randomized, double-blind, vehicle-controlled group study comparing the efficacy and safety of ONEXTON Gel once daily for 12 weeks with vehicle gel in patients 12 years and older with moderate-to-severe acne vulgaris (baseline 20-100 comedonal lesions). Coprimary endpoints included mean absolute change from baseline to Week 12 in comedonal and inflammatory lesion counts and proportion of subjects who achieved at least a 2-grade reduction from baseline at Week 12 in EGSS.3,4 §

Inflammatory lesion reductions at 12 weeks1,2II

Female patients inflammatory reductions chartFemale patients inflammatory reductions chartFemale patients inflammatory reductions chart

Results of a phase 3, multicenter, randomized, double-blind, vehicle-controlled group study comparing the efficacy and safety of ONEXTON Gel once daily for 12 weeks with vehicle gel in patients 12 years and older with moderate-to-severe acne vulgaris (baseline 20-40 inflammatory lesions). Coprimary endpoints included mean absolute change from baseline to Week 12 in comedonal and inflammatory lesion counts and proportion of subjects who achieved at least a 2-grade reduction from baseline at Week 12 in EGSS.3,4 §

§EGSS=Evaluator's Global Severity Score.3,4

EGSS scale: 0 (clear); 1 (almost clear); 2 (mild); 3 (moderate); 4 (severe); 5 (very severe).3,4

Results with once-daily ONEXTON Gel monotherapy after 12 weeks1

16-year-old-female before and after photo 16-year-old-female before and after photo 16-year-old-female before and after photo
31-year-old female before and after photo31-year-old female before and after photo31-year-old female before and after photo

**This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the U.S. at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted. Click here for other terms and conditions that apply.

INDICATION

ONEXTON (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.

IMPORTANT SAFETY INFORMATION

  • ONEXTON Gel is contraindicated in patients with a known hypersensitivity to clindamycin, benzoyl peroxide, any component of the formulation, or lincomycin.
  • ONEXTON Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic‐associated colitis.
  • Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. ONEXTON Gel should be discontinued if significant diarrhea occurs.
  • Orally and parenterally administered clindamycin has been associated with severe colitis, which may result in death.
  • Anaphylaxis, as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately.
  • The most common local adverse reactions experienced by patients in clinical trials were mild and moderate erythema, scaling, itching, burning and stinging.
  • ONEXTON Gel should not be used in combination with erythromycin‐containing products because of its clindamycin component.
  • ONEXTON Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A decision should be made whether to use ONEXTON Gel while nursing, taking into account the importance of the drug to the mother.
  • Patients should be advised to avoid contact with the eyes or mucous membranes.
  • Patients should minimize exposure to natural and avoid artificial sunlight (tanning beds or UVA/B treatment) while using ONEXTON Gel. To minimize exposure to sunlight, protective clothing should be worn and a sunscreen with SPF 15 rating or higher should be used.

Please click here for full Prescribing Information.

References: 1. Data on file. Valeant Pharmaceuticals North America LLC. 2. Zeichner JA. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in adult female patients with facial acne vulgaris. J Clin Aesthet Dermatol. 2015;8(4):21-25. 3. ONEXTON [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014. 4. Pariser DM, Rich P, Cook-Bolden FE, Korotzer A. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014;13(9):1083-1089.

INDICATION

ONEXTON (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.

IMPORTANT SAFETY INFORMATION

  • ONEXTON Gel is contraindicated in patients with a known hypersensitivity to clindamycin, benzoyl peroxide, any component of the formulation, or lincomycin.
  • ONEXTON Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic‐associated colitis.
  • Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. ONEXTON Gel should be discontinued if significant diarrhea occurs.
  • Orally and parenterally administered clindamycin has been associated with severe colitis, which may result in death.
  • Anaphylaxis, as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately.
  • The most common local adverse reactions experienced by patients in clinical trials were mild and moderate erythema, scaling, itching, burning and stinging.
  • ONEXTON Gel should not be used in combination with erythromycin‐containing products because of its clindamycin component.
  • ONEXTON Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A decision should be made whether to use ONEXTON Gel while nursing, taking into account the importance of the drug to the mother.
  • Patients should be advised to avoid contact with the eyes or mucous membranes.
  • Patients should minimize exposure to natural and avoid artificial sunlight (tanning beds or UVA/B treatment) while using ONEXTON Gel. To minimize exposure to sunlight, protective clothing should be worn and a sunscreen with SPF 15 rating or higher should be used.

Please click here for full Prescribing Information.